» Articles » PMID: 12954660

A Castrated Mouse Model of Erectile Dysfunction

Overview
Journal J Androl
Date 2003 Sep 5
PMID 12954660
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

To establish a mouse model for the study of venoocclusive erectile dysfunction, we investigated erectile function in wild-type (WT), castrated (CAST), and castrated mice receiving immediate testosterone replacement (TEST). Adult C57BL6 mice ( approximately 30 g) underwent electrical stimulation of the cavernous nerve in vivo (parameters: 16 Hz frequency, 5 ms duration, 4V stimulatory voltage) with intracavernosal pressure (ICP) monitoring. A total of 55 mice (5 WT, 25 CAST, and 25 TEST) were evaluated. CAST and TEST (5.0 mg/pellet, 60-day release) mice were divided into groups of 5 and evaluated at 24 hours, 72 hours, 1 week, 2 weeks, and 4 weeks. Penile tissue was immunohistochemically stained for alpha-actin (marker for smooth muscle cells) and CD-31 (marker for endothelial cells). Stained slides were analyzed using Image Pro-plus software. In secondary studies, a Doppler flow meter was employed to evaluate penile blood flow. ICP measurements (mm Hg) were significantly decreased in CAST mice at 24 hour-, 72 hour-, 1 week-, 2 week-, and 4-week time points compared with WT mice (41.9 +/- 14.9, 19.1 +/- 4.2, 17.5 +/- 8.2, 14.2 +/- 4.4, and 10.0 +/- 3.8, respectively, vs 50.2 +/- 2.8), but TEST animals maintained or had an increase in ICP in comparison with WT mice (48.0 +/- 1.4, 52.3 +/- 1.3, 60.8 +/- 7.6, 80.5 +/- 2.1, and 81.5 +/- 1.2, respectively). Mean systemic arterial pressure remained approximately 80 mm Hg irrespective of treatment. CAST mouse penis specimens revealed decreased alpha-actin and CD-31 immunoreactivity only at the 4-week interval, compared with WT and TEST specimens. Doppler ultrasound flow rates (centimeter per second), taken before, during, and immediately after cavernous nerve stimulation, were WT 45.4 +/- 7.3, 30.6 +/- 5.2, 55.3 +/- 8.2 vs CAST (2 weeks) 22.2 +/- 2.5, 25.0 +/- 1.5, 23.1 +/- 2.0 vs TEST (2 weeks) 30.5 +/- 6.5, 25.7 +/- 2.0, 45.2 +/- 4.5. This prominently showed that intrapenile flow was not reduced normally during erectile stimulation in CAST mice. This is the first described mouse model of castration-induced veno-occlusive erectile dysfunction. Erectile response abnormalities as measured by ICP and Doppler ultrasound studies in CAST mice may be attributed to hypogonadal effects on erectile tissue function. Morphologic changes in the cavernosal tissue of CAST mice coincide with these abnormalities to some extent. This study defines an androgen-dependent mechanism of veno-occlusive erectile function in the mouse. The castrated mouse model can be applied in future studies of veno-occlusive erectile dysfunction.

Citing Articles

Developmental and functional roles of androgen and interactive signals for external genitalia and erectile tissues.

Hashimoto D, Fujimoto K, Nakata M, Suzuki T, Kumegawa S, Ueda Y Reprod Med Biol. 2024; 23(1):e12611.

PMID: 39372370 PMC: 11456227. DOI: 10.1002/rmb2.12611.


Estrogenic endocrine disruptor exposure directly impacts erectile function.

Cripps S, Marshall S, Mattiske D, Ingham R, Pask A Commun Biol. 2024; 7(1):403.

PMID: 38565966 PMC: 10987563. DOI: 10.1038/s42003-024-06048-1.


A review of experimental techniques for erectile function researches and development of medical technology using animal erectile dysfunction models in sexual and reproductive medicine.

Kataoka T, Hotta Y, Kimura K Reprod Med Biol. 2023; 22(1):e12513.

PMID: 37020643 PMC: 10069627. DOI: 10.1002/rmb2.12513.


A visualization system for erectile vascular dynamics.

Fujimoto K, Hashimoto D, Kashimada K, Kumegawa S, Ueda Y, Hyuga T Front Cell Dev Biol. 2022; 10:1000342.

PMID: 36313553 PMC: 9615422. DOI: 10.3389/fcell.2022.1000342.


Long-term administration of resveratrol and MitoQ stimulates cavernosum antioxidant gene expression in a mouse castration model of erectile dysfunction.

Pierre C, Azeez T, Rossetti M, Gordon B, La Favor J Life Sci. 2022; 310:121082.

PMID: 36252696 PMC: 9746260. DOI: 10.1016/j.lfs.2022.121082.